AT A FRACTION OF THE COST
into empowering people
Technology For All
Bringing you the gold standard of laboratory testing to every patient’s point-of-needs.
Providing real-time PCR results in 20 minutes from sample to results, anywhere.
Enabling rapid clinical decision-making through data management and triage at the Point-of-Care testing.
Making better and faster informed decisions
Accelerate diagnostics turnaround time at a fraction of the cost
Turning informed decisions into empowering people
Diagnostics with rapid and uncompromising accuracy
Turning informed decisions into empowering people
Diagnostics with rapid and uncompromising accuracy
Providing advanced medical technology for all
Redefining healthcare for human clinical management
Laboratory Professional
Healthcare
Provider
Health System Administrator
ABOUT CREDO DIAGNOSTICS
Knowledge Empowering People
Since 2011, Credo Diagnostics has been dedicated to researching and developing revolutionary diagnostic technologies. We have created, manufactured, and commercialized accurate, rapid, and affordable molecular diagnostic solutions for point-of-care testing.
OUR REACH
Making a positive impact on the lives of billions of people around the globe
LATEST
Media News & Product Updates Keep Abreast with the Latest
Miniaturized Real-Time PCR systems for SARS-CoV-2 detection at the Point-of-Care
VitaPCR™ RT-PCR test reaches sensitivity and specificity close to 100% (99,3% and 94,7%, respectively). With this 1.2 kg device, the test is simple and fast,
Comparative practicability and analytical performances of Credo VitaPCR™ Flu A&B and Cepheid Xpert® Xpress Flu/RSV platforms
We herein compared the practicability and analytical performances of VitaPCR™ Flu A&B Assay and Xpert® Xpress Flu/RSV assay, two rapid POC NAATs, by reference to
Performances of the VitaPCR™ SARS‐CoV‐2 Assay during the second wave of the COVID‐19 epidemic in France
Finally, our observations confirm high usability and good appreciation of VitaPCR™ platform for its short duration of analysis (20 min), the little place occupied, and
Current diagnostic tools for coronaviruses–From laboratory diagnosis to POC diagnosis for COVID-19
Several companies in other countries have developed novel molecular POC assays for COVID-19. One example is the VitaPCR™ COVID-19 Assay produced by a Singapore company,
Update on the Detection of the latest SARS-CoV-2 Variant
Singapore, February 5, 2024 – Update on the Detection of the latest SARS-CoV-2 Variant Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring
Update on Detection of Existing Influenza A Variant
Singapore, December 6, 2023 – Update on the Detection of Existing Influenza A Variant Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring
Update on Detection of Existing Influenza A Variant
Singapore, October 5, 2023 – Update on Detection of Detection of Existing Influenza A Variant Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market
Update on Detection of the Latest SARS-CoV-2 Variant BA.2.86
Singapore, September 7, 2023 – Update on Detection of the Latest SARS-CoV-2 Variant Credo Diagnostics Biomedical Pte Ltd is committed to the post-market monitoring of